PURPOSE: High-grade glioma treatment includes ionizing radiation therapy. The high invasiveness of glioma cells precludes their eradication and is responsible for the dismal prognosis. Recently, we reported the down-regulation of MHC class I (MHC-I) products in invading tumor cells in human and mouse GL261 gliomas. Here, we tested the hypothesis that whole-brain radiotherapy (WBRT) up-regulates MHC-I expression on GL261 tumors and enhances the effectiveness of immunotherapy. EXPERIMENTAL DESIGN: MHC-I molecule expression on GL261 cells was analyzed in vitro and in vivo by flow cytometry and immunohistochemistry, respectively. To test the response of established GL261 gliomas to treatment, mice with measurable (at CT imaging) brain tumors were randomly assigned to four groups receiving (a) no treatment, (b) WBRT in two fractions of 4 Gy, (c) vaccination with irradiated GL261 cells secreting granulocyte-macrophage colony-stimulating factor, or (d) WBRT and vaccination. Endpoints were tumor response and survival. RESULTS: An ionizing radiation dose of 4 Gy maximally up-regulated MHC-I molecules on GL261 cells in vitro. In vivo, WBRT induced the expression of the beta2-microglobulin light chain subunit of the MHC class I complex on glioma cells invading normal brain and increased CD4+ and CD8+ T cell infiltration. However, the survival advantage obtained with WBRT or vaccination alone was minimal. In contrast, WBRT in combination with vaccination increased long-term survival to 40% to 80%, compared with 0% to 10% in the other groups (P < 0.002). Surviving animals showed antitumor immunity by rejecting challenge tumors. CONCLUSION: Ionizing radiation can be successfully combined with peripheral vaccination for the treatment of established high-grade gliomas.
PURPOSE: High-grade glioma treatment includes ionizing radiation therapy. The high invasiveness of glioma cells precludes their eradication and is responsible for the dismal prognosis. Recently, we reported the down-regulation of MHC class I (MHC-I) products in invading tumor cells in human and mouse GL261 gliomas. Here, we tested the hypothesis that whole-brain radiotherapy (WBRT) up-regulates MHC-I expression on GL261 tumors and enhances the effectiveness of immunotherapy. EXPERIMENTAL DESIGN: MHC-I molecule expression on GL261 cells was analyzed in vitro and in vivo by flow cytometry and immunohistochemistry, respectively. To test the response of established GL261 gliomas to treatment, mice with measurable (at CT imaging) brain tumors were randomly assigned to four groups receiving (a) no treatment, (b) WBRT in two fractions of 4 Gy, (c) vaccination with irradiated GL261 cells secreting granulocyte-macrophage colony-stimulating factor, or (d) WBRT and vaccination. Endpoints were tumor response and survival. RESULTS: An ionizing radiation dose of 4 Gy maximally up-regulated MHC-I molecules on GL261 cells in vitro. In vivo, WBRT induced the expression of the beta2-microglobulin light chain subunit of the MHC class I complex on glioma cells invading normal brain and increased CD4+ and CD8+ T cell infiltration. However, the survival advantage obtained with WBRT or vaccination alone was minimal. In contrast, WBRT in combination with vaccination increased long-term survival to 40% to 80%, compared with 0% to 10% in the other groups (P < 0.002). Surviving animals showed antitumor immunity by rejecting challenge tumors. CONCLUSION:Ionizing radiation can be successfully combined with peripheral vaccination for the treatment of established high-grade gliomas.
Authors: Neha Vapiwala; Charles R Thomas; Surbhi Grover; Mei Ling Yap; Timur Mitin; Lawrence N Shulman; Mary K Gospodarowicz; John Longo; Daniel G Petereit; Ronald D Ennis; James A Hayman; Danielle Rodin; Jeffrey C Buchsbaum; Bhadrasain Vikram; May Abdel-Wahab; Alan H Epstein; Paul Okunieff; Joel Goldwein; Patrick Kupelian; Joanne B Weidhaas; Margaret A Tucker; John D Boice; Clifton David Fuller; Reid F Thompson; Andrew D Trister; Silvia C Formenti; Mary-Helen Barcellos-Hoff; Joshua Jones; Kavita V Dharmarajan; Anthony L Zietman; C Norman Coleman Journal: Int J Radiat Oncol Biol Phys Date: 2019-05-22 Impact factor: 7.038
Authors: Timothy J Harris; Edward L Hipkiss; Scott Borzillary; Satoshi Wada; Joseph F Grosso; Hung-Rong Yen; Derese Getnet; Tullia C Bruno; Monica V Goldberg; Drew M Pardoll; Theodore L DeWeese; Charles G Drake Journal: Prostate Date: 2008-09-01 Impact factor: 4.104
Authors: W Maes; C Deroose; V Reumers; O Krylyshkina; R Gijsbers; V Baekelandt; J Ceuppens; Z Debyser; S W Van Gool Journal: J Neurooncol Date: 2008-09-12 Impact factor: 4.130